Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases

Portfolio	Key Programs	Indication	Preclinical	Phase I	Phase II	Phase III/Pivotal	FDA Approval
COVID-19 Programs	COVI-TRACE™ (diagnostic) Diagnostic Test 0%* FDA Emergency Use Authorization (EUA) Application Expected COVI-STIX™ (diagnostic) Antigen Test 0%* FDA Emergency Use Authorization (EUA) Application Expected COVI-TRACK™ (diagnostic) Antibody Test 0%* FDA Emergency Use Authorization (EUA) Application Under Review COVI-GUARD™ (treatment) Neutralizing Antibody (IV) in Inpatients 30%* COVI-AMG™ (treatment) Neutralizing Antibody (IV) in Outpatients 30%* COVI-DROPS™ (treatment) Neutralizing Antibody (Intranasal) in Outpatients 10%* COVI-SHIELD™ (treatment) Neutralizing Abs (IV) in Inpatients 10%* COVIDTRAP™ (treatment) ACE2 Receptor Decoy (IV) in Inpatients 10%* ABIVERTINIB (treatment) Severe or Critical COVID-19 in ICU Patients 55%* SALICYN – 30 (treatment) Anti-viral 10%* COVI-MSC (treatment) ARDS due to COVID-19 in ICU Pts 30%*
Immunotherapy	CD38 CAR-T Multiple Myeloma 30%* CD38 DAR-T Multiple Myeloma 10%* CD38 ADC Amyloidosis 30%* Seprehvir™ Solid Tumors 30%* Seprehvec™ Solid Tumors 30%* ABIVERTINIB NSCLC 80%* ADNIC Solid and Liquid Tumors 55%*
Pain	RTX (resiniferatoxin) Epidural route Intractable Pain in Advanced Cancer 55%* Orphan designation RTX (resiniferatoxin) Intra-articular route Moderate to Severe OA 55%*
Lymphatic Delivery	Sofusa® anti-TNF Autoimmune 30%* Sofusa® anti-PD-1 CTCL 30%*

COVID-19 Programs
Key Programs (Indication)	Phase
COVI-TRACE™ (diagnostic) FDA EUA COVI-STIX™ (diagnostic) FDA EUA COVI-TRACK™ (diagnostic) FDA EUA COVI-GUARD™ (treatment) Ph I COVI-AMG™ (treatment) Ph I COVI-DROPS™ (treatment) Preclinical COVI-SHIELD™ (treatment) Preclinical COVIDTRAP™ (treatment) Preclinical ABIVERTINIB (treatment) Ph II SALICYN – 30 (treatment) Preclinical COVI-MSC (treatment) Ph I

Immunotherapy
Key Programs (Indication)	Phase
CD38 CAR-T (Multiple Myeloma) Ph I CD38 DAR-T (Multiple Myeloma) Preclinical CD38 ADC (Amyloidosis) Ph I Seprehvir™ (Solid Tumors) Ph I Seprehvec™ (Solid Tumors) Ph I ABIVERTINIB (NSCLC) PhIII/Pivotal ADNIC (Solid and Liquid Tumors) Ph II

Pain
Key Programs (Indication)	Phase
RTX (resiniferatoxin) Epidural route (Terminal Cancer Pain) Ph II RTX (resiniferatoxin) Intra-articular route (Moderate to Severe OA) Ph II

Lymphatic Delivery
Key Programs (Indication)	Phase
Sofusa® anti-TNF (Autoimmune) Ph I Sofusa® anti-PD-1 (Immuno Oncology) Ph I

Key Programs	Indication	Preclinical	Phase I	Phase II	Phase III/Pivotal	FDA Approval
COVID-19 Programs
COVISTIX™ (diagnostic) Rapid Antigen Test 0%* Emergency Use Authorization (EUA) in Mexico (COFEPRIS), Brazil (ANVISA), and CE Marked in Europe COVIMARK™ (diagnostic) Rapid Antigen Test 0%* Application submitted in the US and Canada for Emergency Use Authorization (EUA) VIREX (diagnostic) At Home Diagnostic 60.2%* EUA Enabling Studies in Q3 2022 OQORY™ (COVI-MSC) ARDS due to COVID-19 in ICU Patients 82%* Pivotal Trial in Brazil                           OVYDSO (Olgotrelvir) Anti-viral (Oral Pill) 40%* Omicron mRNA Vaccine Vaccine 20%*
Key Programs	Indication	Preclinical	Phase I	Phase II	Phase III/Pivotal	FDA Approval
Immunotherapy
FUJOVEE™ (Abivertinib) NSCLC 82%* FUJOVEE™ (Abivertinib) B Cell Lymphomas 60.2%* FUJOVEE™ (Abivertinib) Prostate 20%* PD-L1 (Socazolimab)* SCLC 82%* *In Partnership with Lee’s Pharm in China PD-L1 (STI-3031)** Cervical Cancer 82%* **In US and in partnership with ImmuneOncia in Korea CD47 Solid Tumors 40%* CD38 DAR-T Multiple Myeloma 40%* CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, and esophageal 40%* TROP2 ADC* Solid Tumors 40%* Seprehvec™ oncolytic virus Solid Tumors; CNS Tumors 40%* BCMA ADC Liquid Tumors 20%* Bevacizumab-ADNAB™ Endometrial Cancer 40%* In partnership with Mayo Clinic Bevacizumab-ADNAB™ Ovarian Cancer 40%* In partnership with Mayo Clinic Rituximab-ADNAB™ B-cell Lymphomas 40%* In partnership with Mayo Clinic Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma 40%*
Key Programs	Indication	Preclinical	Phase I	Phase II	Phase III/Pivotal	FDA Approval
Pain
ZTlido® 1.8% Postherpetic Neuralgia - PHN 99.8%* Gloperba® Treatment of Gout (Oral) 99.8%* SEMDEXA (SP-102) Lumbar Radicular/Sciatica Pain 82%* SP-103 (Lidocaine Topical System 5.4%) Acute Back Pain 60.2%* SP-104 (Delayed Burst Low Dose Naltrexone) Fibromyalgia 20%* RTX (resiniferatoxin) Epidural injection Intractable Pain in Advanced Cancer 60.3%* Orphan designation RTX (resiniferatoxin) Intra-articular route Moderate to Severe Knee OA Pain 60.2%*
Key Programs	Indication	Preclinical	Phase I	Phase II	Phase III/Pivotal	FDA Approval
Lymphatic Drug Delivery
Sofusa® anti-TNF Autoimmune (RA) 40%* Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma 40%* Sofusa® anti-CTLA-4 Melanoma 40%* In partnership with Mayo Clinic

COVID-19 Programs
Key Programs (Indication)	Phase
COVISTIX™ (diagnostic) FDA EUA COVIMARK™ (diagnostic) FDA EUA VIREX (diagnostic) PH III FUJOVEE™ (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III OVYDSO (Olgotrelvir) Ph II Omicron mRNA Vaccine Preclinical

Immunotherapy
Key Programs (Indication)	Phase
FUJOVEE™ (Abivertinib) Ph III FUJOVEE™ (Abivertinib) Ph II FUJOVEE™ (Abivertinib) Preclinical PD-L1 (Socazolimab)* Ph III PD-L1 (STI-3031)** Ph III CD47 (Solid Tumors) Ph I CD38 DAR-T (Multiple Myeloma) Ph I CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, and esophageal) Ph I TROP2 ADC* (Solid Tumors) Ph I Seprehvec™ oncolytic virus (Solid Tumors; CNS Tumors) PH I BCMA ADC (Liquid Tumors) Preclinical Bevacizumab-ADNAB™ (Endometrial Cancer) Ph I Bevacizumab-ADNAB™ (Ovarian Cancer) Ph I Rituximab-ADNAB™ (B-cell Lymphomas) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I

Pain
Key Programs (Indication)	Phase
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) FDA Approval Gloperba® 1.8% Treatment of Gout (Oral) FDA Approval SEMDEXA (SP-102) Ph III SP-103 (Lidocaine Topical System 5.4%) Ph II SP-104 (Delayed Burst Low Dose Naltrexone) Preclinical RTX (resiniferatoxin) Epidural injection Ph II RTX (resiniferatoxin) Intra-articular route Ph II

Lymphatic Delivery
Key Programs (Indication)	Phase II
Sofusa® anti-TNF (Autoimmune RA) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I Sofusa® anti-CTLA-4 (Melanoma) Ph I